MediWound (NASDAQ:MDWD) Shares Cross Below 50 Day Moving Average - Should You Sell?

Key Points

• MediWound shares fell below their 50-day moving average, trading as low as $13.30 versus the $13.58 average, and last changing hands at $13.51.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $33.00 target price; Oppenheimer lowered its target to $30.00 from $32.00.
• The company reported a quarterly loss of $0.77 per share, slightly worse than estimates, despite revenue of $3.09 million exceeding forecasts; analysts expect a full-year loss of $2.37 per share.

MediWound Ltd. (NASDAQ:MDWD - Get Free Report) passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $13.58 and traded as low as $13.30. MediWound shares last traded at $13.51, with a volume of 49,885 shares traded.

Analysts Set New Price Targets

MDWD has been the subject of several research reports. Alliance Global Partners restated a "buy" rating on shares of MediWound in a research report on Wednesday, September 16th. Oppenheimer reiterated an "outperform" rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Wall Street Zen raised shares of MediWound from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 26th. Weiss Ratings cut shares of MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, September 8th. Finally, TD Cowen reaffirmed a "buy" rating on shares of MediWound in a report on Thursday, September 24th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.00.

MediWound Trading Down 0.1%

The firm's fifty day moving average price is $13.58 and its 200-day moving average price is $14.91. The company has a market cap of $173.60 million, a price-to-earnings ratio of -7.51 and a beta of 0.09.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.The business had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. As a group, research analysts anticipate that MediWound Ltd. will post -2.37 EPS for the current year.

Insider Activity at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 9.20% of the stock is currently owned by corporate insiders.

Institutional Trading of MediWound

An institutional investor recently raised its position in MediWound stock. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) by 22.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 71,000 shares of the biopharmaceutical company's stock after buying an additional 13,196 shares during the period. Clal Insurance Enterprises Holdings Ltd owned approximately 0.55% of MediWound worth $1,311,000 as of its most recent filing with the SEC. 46.83% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd. NASDAQ: MDWD is a biotechnology company focused on developing and commercializing innovative therapies for complex wounds. The company's products are designed to remove damaged tissue, support wound healing and address unmet needs in burn care and chronic wounds.

MediWound's lead commercial product is NexoBrid, a topical bromelain-based enzymatic treatment used to remove eschar—the dead tissue that can form after severe thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel, and is marketed for use in the treatment of deep partial-thickness and full-thickness burns.

The company is also developing EscharEx, an investigational topical treatment intended to enzymatically debride chronic wounds, including venous leg ulcers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.